Hepcludex (Bulevirtide)

Hepcludex is indicated for specific clinical situations related to hepatitis D virus infection.

• Chronic hepatitis D infection in adults with compensated liver disease.
• Patients who have documented HBV co‑infection, as hepatitis D requires hepatitis B surface antigen for replication.
• Cases where antiviral therapy is needed to prevent progression to cirrhosis.
• Use as part of a comprehensive management plan that includes monitoring of liver function.
• May be considered when other hepatitis D therapies are unavailable or contraindicated.

The safety profile of Hepcludex includes several reported adverse events, which are categorized by frequency and severity.

Common

• Injection site pain or erythema.
• Mild fatigue.
• Transient headache.
• Elevated liver enzymes (ALT/AST) that are usually reversible.

Serious

• Severe hypersensitivity reactions, including rash or anaphylaxis.
• Significant hepatic decompensation or worsening liver function.

Before initiating Hepcludex, clinicians should evaluate several precautionary factors to ensure safe use.

• Confirm compensated liver disease status; decompensated cirrhosis requires careful assessment.
• Assess for active HBV infection and ensure appropriate HBV management.
• Monitor liver function tests regularly during therapy.
• Use with caution in pregnant or breastfeeding women, as safety data are limited.
• Evaluate renal function, although no specific contraindication is known.
• Review patient’s allergy history, especially to injectable products.
• Consider potential immunosuppression that could affect infection risk.

Hepcludex may interact with other medicines, and the nature of the interaction guides clinical decisions.

Avoid

• Concomitant use of potent NTCP inhibitors that could alter bulevirtide pharmacodynamics (experimental agents).
• Live vaccines administered during treatment, due to possible reduced immune response.

Use with caution

• Other antiviral agents targeting hepatitis B (e.g., tenofovir, entecavir) as combined effects on viral replication are not fully characterized.
• Immunosuppressive drugs, which may affect infection control.
• Medications that significantly affect liver enzymes, potentially altering bulevirtide metabolism.